副教授，硕士生导师，中山大学百人计划引进人才

 

研究方向

1. 抗登革热、乙肝等病毒药物的研发

2. 探针工具的设计合成

 

工作经历

2022.09 – 至今  中山大学公共卫生学院（深圳） 副教授

2016.09 - 2022.08  美国德克萨斯大学医学部（UTMB）博士后

2015.05 - 2016.08  康龙化成（北京）新药技术有限公司 研究员

2014.07 - 2015.04  上海源力生物技术有限公司（江苏恒瑞医药公司子公司）研究员

 

教育经历

2009.09 - 2014.07  中国科学院上海药物研究所  药学化学  理学博士

2005.09 - 2009.07  中国药科大学  药学理科基地班  理学学士

 

承担项目

1.国家自然科学基金面上项目（2026-2029），在研，主持

2.中山大学“百人计划”启动项目（2022-2025），在研，主持

3.中山大学高校基本科研业务费青年教师培育项目（2024-2024），结题，主持

 

发表论文 ：

  1. Huo, J., Chen, H., Qiu, X., Wang, G., Sánchez-Céspedes, J., Liu, K. *, Zhou, J. *, Xu, J*. Small-Molecule Strategies against Human Adenoviruses: Progress, Challenges, and Future Perspectives. J. Med. Chem. 2025, 68(13): 13186-13217.
  2. Huo, J. #, Xiao, J. #, Zhang, Y. #, Qiu, X., Huang, X., Wang, G., Wang, J., Liu, K. *, Xu, J. * Salicylamide derivatives as potent HBV inhibitors: insights into structure–activity relationships. RSC Medicinal Chemistry 2025, 16(7): 3158-3173.
  3. Xu, J. #, Shi, S. #, Liu, G., Xie, X., Li, J., Bolinger, A. A., Chen, H., Zhang, W., Shi, P. Y., Liu, H. *, Zhou, J. * Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators. Eur. J. Med. Chem. 2023, 246: 114998.
  4. Xu, J., Xue, Y., Bolinger, A. A., Li, J., Zhou, M., Chen, H., Li, H., Zhou, J. Therapeutic potential of salicylamide derivatives for combating viral infections. Med. Res. Rev. 2023, 43(4): 897-931.
  5. Xu, J. #; Kim, H. #; Dong, J. #; Chen, H.; Xu, J.; Ma, R.; Zhou, M.; Wang, T.; Shen, Q. *; Zhou, J. * Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents. Eur J Med Chem 2022, 234, 114229.
  6. Samrat, S. K. #; Xu, J. #; Xie, X.; Gianti, E.; Chen, H.; Zou, J.; Pattis, J. G.; Elokely, K.; Lee, H.; Li, Z.; Klein, M. L.; Shi, P.-Y.; Zhou, J. *; Li, H. * Allosteric inhibitors of the main protease of SARS-CoV-2. Antiviral Res. 2022, 205, 105381.
  7. Li, Z. #; Xu, J.#; lang, Y. #; Wu, X., Hu, S., Samrat, S., Tharappel, A., Butler, D.; Song, Y.; Zhang, Q.-Y.; Zhou, J.; Li, H. *In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus. Acta Pharm. Sin. B. 2021, 12, 1662-1670.
  8. Xu, J.; Xue, Y.; Zhou, R.; Shi, P.-Y.; Li, H.; Zhou, J. * Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. Med. Res. Rev.2021, 41, 1375-1426.
  9. Xu, J. #; Berastegui-Cabrera, J. #; Carretero-Ledesma, M.; Chen, H.; Xue, Y.; Wold, E. A.; Pachón-Díaz, J.; Zhou, J. *; Sanchez-Cespedes, J. * Discovery of a small molecule inhibitor of human adenovirus capable of preventing escape from the endosome. Int. J. Mol. Sci. 2021, 22(4), 1617.
  10. Xu, J. #; Wu, W. #; Chen, H.; Xue, Y.; Bao, X. *; Zhou, J. * Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses. Bioorg. Med. Chem. 2021, 39, 116157.
  11. Xu, J. #; Berastegui-Cabrera, J. #; Ye, N.; Carretero-Ledesma, M.; Pachón-Díaz, J.; Chen, H.; Pachón-Ibáñez, M. E.; Sánchez-Céspedes, J.*; Zhou, J. * Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors. J. Med. Chem. 2020, 63, 12830-12852.
  12. Xu, J. #; Berastegui-Cabrera, J. #; Chen, H.; Pachón, J.; Zhou, J. *; Sánchez-Céspedes, J. * Structure–Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection. J. Med. Chem. 2020, 63, 3142-3160.
  13. Li, Z.#; Xu, J.#; Lang, Y.; Fan, X.; Kuo, L.; D’Brant, L.; Hu, S.; Samrat, S. K.; Trudeau, N.; Tharappel, A. M.; Rugenstein, N.; Koetzner, C. A.; Zhang, J.; Chen, H.; Kramer, L. D.; Butler, D.; Zhang, Q.-Y.; Zhou, J. *; Li, H. * JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo. ACS Infect. Dis. 2020,6, 2616-2628.
  14. Xu, J.; Shi, P.-Y.; Li, H.; Zhou, J. * Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect. Dis. 2020,6, 909-915.
  15. Xu, J. #; Xie, X. #; Chen, H.; Zou, J.; Xue, Y.; Ye, N.; Shi, P.-Y. *; Zhou, J. * Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors. Bioorg. Med. Chem. Lett. 2020,30, 127162.
  16. Xu, J. #; Xie, X. #; Ye, N.; Zou, J.; Chen, H.; White, M. A.; Shi, P.-Y. *; Zhou, J. * Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione Analogues as Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection. J. Med. Chem. 2019, 62, 7941-7960.
  17. Xu, J. #; Pachon-Ibanez, M. E. #; Cebrero-Cangueiro, T. #; Chen, H.; Sanchez-Cespedes, J. *; Zhou, J. * Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates. Bioorg. Med. Chem. Lett. 2019, 29, 1399-1402.
  18. Fan, X. #; Xu, J. #; Files, M.; Cirillo, J. D.; Endsley, J. J.; Zhou, J.; Endsley, M. A. * Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing). Tuberculosis (Edinb.) 2019, 116S, S28-S33.
  19. Xu, J.; Wold, E. A.; Ding, Y.; Shen, Q.; Zhou, J. * Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection. Molecules 2018, 23, 474.
  20. Xu, J. #; Ai, J. #; Liu, S.; Peng, X.; Yu, L.; Geng, M. *; Nan, F. * Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors. Org. Biomol. Chem. 2014, 12, 3721-3734.
  21. Li, Z.; Tharappel, A. M.; Xu, J.; Lang, Y.; Green, C. M.; Zhang, J.; Lin, Q.; Chaturvedi, S.; Zhou, J.; Belfort, M.; Li, H., Small-molecule inhibitors for the Prp8 intein as antifungal agents. . Proc. Natl. Acad. Sci. U. S. A. 2021,118, e2008815118.
  22. Liu, X.; Xu, J.; Zhou, J.; Shen, Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes & Diseases.2021, 8, 448-462.
  23. Samrat, S. K.; Xu, J.; Li, Z.; Zhou, J.; Li, H. Antiviral Agents against Flavivirus Protease: Prospect and Future Direction. Pathogens 2022, 11, 293.
  24. Yu, Y.; Yang, W.; Bilotta, A. J.; Yu, Y.; Zhao, X.; Zhou, Z.; Yao, S.; Xu, J.; Zhou, J.; Dann, S. M.; Li, Y.; Cong, Y. STING controls intestinal homeostasis through promoting antimicrobial peptide expression in epithelial cells. The FASEB Journal.2020,34, 15417-15430.
  25. Davis-Reyes, B. D.; Smith, A. E.; Xu, J.; Cunningham, K. A.; Zhou, J.; Anastasio, N. C. Subanesthetic Ketamine with an AMPAkine Attenuates Motor Impulsivity in Rats. Behav. Pharmacol. 2021, 32, 335-344.

  26. Cummins, C. B.; Wang, X.; Xu, J.; Hughes, B. D.; Ding, Y.; Chen, H.; Zhou, J.; Radhakrishnan, R. S. Antifibrosis Effect of Novel Oridonin Analog CYD0618 Via Suppression of the NF-κB Pathway. J. Surg. Res. 2018, 232, 283-292.

     

招生信息

招收硕士生2人左右/年。欢迎对抗病毒小分子药物研发感兴趣的同学加入联系方式：xujm37@mail.sysu.edu.cn。